Clinical trials: Head and Neck Tumours
Head and Neck Neoplasms
Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Head and Neck Neoplasms.
- Trial name
- IRE (NCT02335112)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Esophageal Cancer
CPAP for Esophageal Cancer With Radiotherapy
The goal of this clinical trial is to test the use of CPAP in patients with esophgaeal cancer undergoing radiotherapy. The main questions it aims to answer are: does use of CPAP decrease exposure of normal lung to radiation? does…
- Trial name
- TROS-7 (NCT06037902)
- Testing
- CPAP
- Where
- Israel
- Volunteers
- 44 people
- Sponsor
- Sheba Medical Center
Solid Tumor, Adult
Study of DF9001 in Patients With Advanced Solid Tumors
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases.
- Trial name
- NCT05597839
- Testing
- DF9001, KEYTRUDA® (pembrolizumab)
- Where
- 17 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dragonfly Therapeutics
Thyroid Cancer
Analgesic Efficacy of Bilateral Superficial Cervical Plexus Block in Robot-assisted Endoscopic Thyroidectomy Using a Transaxillary Approach
This study was designed to investigate the analgesic effect of bilateral superficial cervical plexus block in patients undergoing robot-assisted endoscopic thyroidectomy.
- Trial name
- NCT01325857
- Testing
- Bilateral superficial cervical plexus block, Control group
- Where
- South Korea
- Volunteers
- 97 people
- Sponsor
- Yonsei University
Head and Neck Cancer
Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation
The purpose of this study is to investigate the clinical value of serial quantitative [F-18] FLT as a PET imaging tool in head and neck cancer patients clinically scheduled with radiation or radiation-chemotherapy combination in…
- Trial name
- NCT00894101
- Testing
- [F-18] FLT
- Where
- United States
- Sponsor
- University of California, Irvine
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Neoplasms, Stomach Neoplasms
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
The purpose of this study is to evaluate the progression free survival of capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) in previously untreated metastatic esophagogastric adenocarcinomas.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis
- Trial name
- XAGastric (NCT00447330)
- Testing
- capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Duke University
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
Patients with MGIN, HGIN or flat-type early SCCA of the esophagus will be treated on 3 month intervals with Radiofrequency Ablation (RFA) until complete eradication (CR: no MGIN or worse in the biopsies) will be achieved.
- Trial name
- NCT02047305
- Testing
- Radiofrequency Ablation
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Covidien, GI Solutions
Prostate Cancer, Head and Neck Cancer
Predictors of Normal Tissue Response From the Microenvironment in Radiotherapy for Prostate and Head-and-neck Cancer
The main idea behind MICRO-LEARNER is to provide new insights about the response of healthy tissues to radiation by using information from the micro-environment obtained by biological measurements and imaging.
- Trial name
- MICROLEARNER (NCT03294122)
- Testing
- External beam radiotherapy for prostate cancer, External beam radiotherapy for head and neck cancer
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Oesophageal Squamous Cell Carcinoma
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC).
- Trial name
- NCT07405151
- Testing
- I-DXd, Rescue Medication
- Where
- 32 sites in United States, Brazil and 9 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck
Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC
Phase II trial evaluating to assess the feasibility and efficacy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC of Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in…
- Trial name
- DURTRE-RAD (NCT03624231)
- Testing
- Durvalumab, Tremelimumab, Radiotherapy
- Where
- 3 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Ulrich Keilholz
Oral Leukoplakia
Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia
Oral leukoplakia is the most commonly occurring oral premalignant disorder. It has an overall prevalence rate of 1-4% with highest prevalence rate of 10.54% in Asian countries.
- Trial name
- NCT04251845
- Testing
- topical melatonin
- Where
- India
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Nasopharyngeal Cancer, Epstein-Barr Virus Infections
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
The purpose of this study is to evaluate the efficacy (clinical benefit rate) of MVA EBNA1/LMP2 vaccine in patients with persistent, recurrent or metastatic nasopharyngeal carcinoma, and its impact on disease progression.
- Trial name
- NCT01094405
- Testing
- Recombinant Epstein-Barr Virus (EBV) Vaccine
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- Chinese University of Hong Kong
Advanced Solid Tumor, Cholangiocarcinoma
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and…
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05253053
- Testing
- TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
- Where
- 9 sites in China
- Volunteers
- 84 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Erythroplakia, Leukoplakia
Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions
This phase I trial tests whether metformin works in reducing the annual transformation (development of invasive cancer) of oral precancerous lesions into cancerous lesions.
- Conditions
- Erythroplakia, Leukoplakia, Oral Cavity Carcinoma, Proliferative Verrucous Leukoplakia
- Trial name
- NCT05536037
- Testing
- Metformin, Biopsy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Head & Neck Cancer
Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer Surgery
The goal of this clinical trial is to evaluate the effectiveness of a multidisciplinary specialist nurse-led perioperative nursing management model for patients undergoing head and neck cancer surgery.
- Trial name
- NCT07622381
- Testing
- Multidisciplinary Specialist Nurse-Led Perioperative Nursing Management, Routine Perioperative Nursing Care
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E)
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E), Squamous Cell Cancer of the Head and Neck (Part E)
- Trial name
- NCT02637531
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 219 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
This study is open to adults with advanced head and neck cancer, skin cancer, or non-small cell lung cancer. People can take part if previous treatments were not successful.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05068102
- Testing
- BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.